© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses a phase Ia study examining atezolizumab in patients with urothelial bladder cancer.